Qritive, headquartered in Singapore, with US operations in San Diego and India operations in Pune, has raised $7.5 million in a funding round led by MassMutual Ventures, supported by SEEDS Capital and Exfinty Venture Partners. Qritive will use this new capital to drive geographical expansion, expand its product portfolio and support regulatory clearances.

Using artificial intelligence (AI), Qritive solutions provide fast and accurate interpretations of pathology whole slide image scans within seconds, reducing time to treatment, and increasing accuracy for cancer care.

Qritive’s solutions are CE certified and also approved by Singapore Health Sciences Authority (HSA) for clinical use. Qritive’s technology helps accelerate cancer diagnosis across multiple cancer types including colon, prostate, lymph node, and breast and includes a robust set of tools for immunohistochemistry. 

The startup's Pantheon digital pathology platform is a one-of-a-kind platform that brings together tools for case management, reporting, slide viewing and analysis, telepathology, synoptic reporting, and LIS integration. Qritive aims to create an open-pathology environment and Pantheon is agnostic to microscopes and IT enabling easy integration of third party AI solutions.